- Filgrastim, sold
under the
brand name
Neupogen among others, is a
medication used to
treat low
neutrophil count. Low
neutrophil counts may
occur with HIV/AIDS...
-
granulocyte colony-stimulating
factor (G-CSF),
leading to the
development of
Neupogen (filgrastim). In
October 1988,
Gordon Binder was
named CEO, succeeding...
-
obtained the
first approval of FDA. Sandoz's
Zarxio is
biosimilar to Amgen's
Neupogen (filgrastim),
which was
originally licensed in 1991. This is the first...
- and
arthritis treatment.
Neulastim (pegfilgrastim), for neutropaenia.
Neupogen (filgrastim), for neutropaenia.
Nutropin (somatropin), for
growth hormone...
- support,
which was
under patent protection in the US as late as 2013 (as
Neupogen by Amgen),
while that
patent protection expired in the EU in 2008; Higher...
-
filgrastim on
February 20, 1991
marketed by
Amgen with the
brand name
Neupogen. It was
initially approved to
reduce the risk of
infection in patients...
-
rheumatoid arthritis,
ankylosing spondylitis, and COVID-19. CFU-GM
Filgrastim (
Neupogen, a
granulocyte colony-stimulating
factor (G-CSF) analog) Granulocyte-macrophage...
-
counterfeit Procrit, as well as
counterfeit and
misbranded Serostim and
Neupogen.
Procrit is an
injectable drug used in the
treatment of anemia, Serostim...
-
partnership with
Adello Biologics (for the
collaborative development of
Neupogen and
Neuasta biosimilars) and a 2018
partnership with
mAbxience (for the...
- for the
recombinant granulocyte colony-stimulating factor, the
basis for
neupogen and neulasta,
earning the
institute over $100 million. In 2000, former...
